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Abstract
Objective: few data are available about the efficacy of
maraviroc (Mvc) during routine use. we characterized
indications for Mvc use and the efficacy of Mvc in
clinical practice. 
Methods: Thirty-two patients treated with Mvc at our
institution  between  2006  and  2009  were  included.
Genotypic (n = 31) and phenotypic (n = 13) tropism
analysis was performed. we determined indications for
Mvc use, characteristics of antiretroviral combination
partners and treatment outcome. 
Results: complete suppression of viral replication was
achieved in 78% after 6 months. a median increase of
124 cd4+ cells/ﾵl after 6 months was observed. con-
cordance between phenotypic and genotypic tropism
was found in 75%. Indications for Mvc treatment in-
cluded treatment failure (n = 15), intolerance to previ-
ous antiretrovirals (n = 6) and add-on Mvc for inten-
sification without changing the current regimen (n =
11). The add-on strategy was used in patients with a
relatively low viremia in order to achieve complete vi-
ral load suppression or in situations with suppressed
viral load but judged as unstable due to an extensive
resistance pattern. salvage drugs most frequently com-
bined with Mvc were darunavir (n = 14) and ralte-
gravir (n = 14).
The genotypic assay had predicted cxcR4 tropism
in 5 patients, using a false positive rate (fPR) of 20%.
lowering the fPR to 5% predicted ccR5 tropism in 4
cases,  still  resulting  in  sustained  complete  viral  re-
sponse under Mvc use. 
Conclusions: Mvc containing salvage regimens achieve
relevant  cd4  cell  increases  and  high  viral  response
rates.  In  patients  with  few  remaining  treatment  op-
tions it may be justified to lower the fPR-cutoff to
5%  when  predicting  the  coreceptor  usage.  Hereby,
Mvc could still be applied in selected patients with
otherwise limited treatment options. 
Key words: ccR-5, cxcR-4, salvage, genotype, resis-
tance testing
InTRoducTIon
HIv-1 enters target cells through interaction between
its envelope glycoprotein (gp120) and the cd4 recep-
tor and a chemokine co-receptor on the human cell.
ccR5 and cxcR4 are the two principal co-receptors
involved in HIv entry in vivo. viruses with an exclu-
sive  affinity  for  the  ccR5  co-receptor  are  called
ccR5-tropic  (R5),  whereas  those  viruses  binding  to
the cxcR4 co-receptor are known as cxcR4-tropic
(x4). R5 viruses predominate during early phases of
HIv-infection,  whereas  x4  strains  are  mainly  found
during  advanced  stages  of  disease  [1].  In  some  pa-
tients, both x4 and R5 tropic viruses are found con-
currently, named dual or mixed viral populations.
Maraviroc (Mvc) is the first ccR5 co-receptor in-
hibitor.  Because  of  its  mode  of  action  the  use  of
Mvc is restricted to patients harboring virus able to
bind only to the ccR5 receptor. The selection of usu-
ally  pre-existing  virus  strains  able  to  bind  to  the
cxcR4 receptor is the most important mechanism to
evade  ccR5  antagonists.  Thus,  a  major  challenge 
prior to the use of Mvc is the obligatory tropism
testing.  Tropism  testing  is  used  to  identify  patients
most likely to benefit from treatment regimens that
include a ccR5 antagonist and to monitor patients 
on treatment for the emergence of virus populations
that  have  switched  their  coreceptor  usage.  Tropism
can be assessed by phenotypic [2] and genotypic as-
says [3].
In two large trials in patients with multiple class re-
sistance, MoTIvaTE 1 and 2, it was shown that Mvc
plus optimized background treatment (oBT) was as-
sociated with greater virologic and immunologic effi-
cacy as compared to placebo plus oBT [4]. simultane-
ously to the introduction of Mvc in 2007, various an-
tiretroviral drugs such as the protease inhibitor (PI)
darunavir  (dRv),  the  integrase  inhibitor  raltegravir
(Ral)  or  the  second  generation  non-nucleoside  re-
verse-transcriptase  inhibitor  (nnRTI)  etravirine
(ETR) were newly introduced. due to these new treat-
ment options, current treatment guidelines now state
that the goal of antiretroviral therapy is viral load (vl)
suppression to <50 copies /ml for all patients, includ-
ed those with heavy pre-treatment [5]. 
It appears particularly important to position Mvc
in  the  clinical  context  of  the  widened  spectrum  of
available treatment options and it remains a challenge
to define situations in which this new drug should be
used in the clinical routine [6]. In this prospective ob-
servational study we analysed the characteristics of all
patients treated with Mvc at our institution between
2006 and 2009 to obtain information on the optimal
use of Mvc in routine clinical practice.
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In the outpatient clinic of the department of Gas-
troenterology, Hepatology and Infectious diseases of
d￼sseldorf university a total of 32 treatment-experi-
enced  patients  received  Mvc  for  a  minimum  of  6
months since 2006. They were prospectively followed
for a median of 16 months (interquartile range 12-21
months).  In addition, 55 patients had been tested for
their  viral  coreceptor  usage,  but  x4-using  viruses
were reported and therefore Mvc could not be pre-
scribed. 
we determined indications for Mvc use, the most
frequent  combinations  with  other  antiretrovirals  as
well as the number of new combination partners, co-
morbidities  and  treatment  outcome.  all  patients  re-
ceived  an  analysis  of  the  receptor  status  (ccR5  or
cxcR4), and we performed a comparative evaluation
of phenotypic assay (Trofile test) and genotypic tro-
pism testing. By additional RT/PR + gp41 genotypic
resistance analysis, we determined the sensitivity score
as an indicator for the number of effective additional
drugs in the oBT.
dEfInITIons
Salvage  drugs: This term comprised darunavir, ralte-
gravir,  etravirine,  enfuvirtide,  and  tipranavir  (dRv,
Ral, ETR, Enf and TPv).
Partial treatment response: Patient reaches a vl below
400 copies /ml 3 months after starting a regime con-
taining Mvc, but cannot be suppressed below vl de-
tection limit of 50 copies /ml after 6 months.
Complete  treatment  response: after  starting  a  Mvc
containing regimen, the vl is suppressed below detec-
tion limit of 50 copies /ml at 3 months or 6 months,
respectively.
Sustained complete treatment response: after starting a
Mvc containing regimen, the vl is suppressed below
detection limit of 50 copies /ml until last observation. 
Primary  treatment  failure: Patient  cannot  be  sup-
pressed below a vl of 400 copies /ml 3 months after
starting a regime containing Mvc. 
Secondary  treatment  failure: after  a  complete  treat-
ment response, the vl again rises to detectable levels
at  two  separate  time  points  under  continued  treat-
ment. 
GEnoTyPIc assay foR TRoPIsM TEsTInG
In  the  routine  tropism  testing,  viral  Rna  is  always
first analyzed, if it yields no result, proviral dna is se-
quenced. Rna is preferentially considered, as dna-
sequencing  results  tend  to  overestimate  x4  variants.
viral Rna and proviral dna from PBMcs were iso-
lated, the v3 loop from the gp120 region (v3) ampli-
fied and sequenced as previously described [7], using
the following primers 6206EcoRI: 5ﾴ- aGaGcaGa
aTTcaGTGGcaaTGaGaGT  -3ﾴ  (nt  6206-6232)
and  7785R:  5ﾴ-  aGTGcTTccTGcTGcTccyaaG
aaccc-3ﾴ  (nt  7785-7811).  The  v3  sequences  were
analyzed  using  the  geno2pheno[coreceptor]  tool
(http://www.genafor.org) to predict the viral tropism
using a false positive rate (fPR) cutoff of 20%. fPR is
the probability that “real“ R5 viruses are predicted as
x4. a high fPR cutoff (20%) is used to ensure a most
conservative prediction with the result that only few
R5 predictions will correspond to “real“ x4 samples,
and  therefore  to  minimize  the  risk  of  prescribing
Mvc to patients having x4 viruses. In some patients
with severely limited treatment options a fPR of 5%
was also applied for the decision whether to use Mvc
so that these patients would not have been deprived of
an  important  option  because  of  a  too  conservative
prediction (patients #14, 15, 18, 26). 
PHEnoTyPIc assay foR TRoPIsM TEsTInG
(TRofIlE TEsT)
samples  were  prepared  as  indicated  by  Monogram
(Monogram Biosciences, san francisco, ca, usa) and
sent to be tested with the Trofile assay. This phenotyp-
ic  test  uses  recombinant  HIv-1  pseudo  viruses  and
different reporter cell lines for differentiation between
x4- and R5 tropism. 
cuMulaTIvE sEnsITIvITy scoRE (css) foR
oPTIMIzEd BacKGRound TREaTMEnT (oBT)
The number of active drugs in the oBT concomitant to
Mvc administration was calculated with the prediction
tools  geno2pheno[integrase]  (http://www.genafor.org)
and HIv grade tool (http://www.hiv-grade.de). To cal-
culate the genotypic sensitivity score, values between 0
and 1.5 were assigned to each drug according to its pre-
sumed potency in the oBT as follows:
nRTIs: fully active =1; intermediate =0.3; resistant =0;
nnRTIs (Efv, nvP), T-20, Ral: fully active =1.5;
resistant =0 
nnRTIs (ETR): fully active =1.5; intermediate =0.75;
resistant =0
PIs: fully active =1.5; intermediate =0. 5; resistant =0
The calculation of genotypic sensitivity scores is an
established  procedure  for  comparative  prediction  of
virologic outcomes according to genotypic resistance
results [8, 9]. for calculation of the css, a substance
was only scored as fully active if drug sensitivity was
shown in all previously performed analyses.
REsulTs
Table 1 depicts the most important baseline character-
istics of the study group. Twenty-four patients (75%)
were heavily pre-treated (i.e. ≥ 5 previous therapies)
with a median number of 9 previous regimens prior to
Mvc use and a median age of 47 years at the time of
Mvc start (interquartile range 40-53 years).
IndIcaTIons foR sTaRTInG Mvc
Patients were divided into a group with detectable vl
prior  to  the  change  to  a  regimen  containing  Mvc
(group a, n = 25) and another group with a vl below
the detection limit at the time of starting Mvc (group
B, n = 7) (Table 1). In group a, the 3 indications for
changing to a Mvc containing antiretroviral regimen
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mutations  (n  =  15),  treatment  failure  without  de-
tectable resistance mutations (probably due to non-ad-
herence because of intolerance to their previous PI-
containing regimen) (n = 3) and patients with a rela-
tively low viremia (range 50-1200 copies /ml), thus re-
quiring add-on Mvc for intensification of their regi-
men (n = 7). In 4 of these 7 patients, a full suppres-
sion of vl was achieved at month 3. after 6 months
all 7 patients showed complete vl suppression.
In group B, reasons for a change to Mvc were in-
tolerance of the previous regimen in 3 cases and add-
on Mvc to a virologically successful regimen in order
to achieve an intensification of the regimen (n = 4).
Reasons  for  regimen  intensification  for  these  4  pa-
tients in group B were as follows:
one patient (#29) had never been sufficiently sup-
pressed during the last 13 years. with the use of 3 new
drugs his vl already was below 50 copies /ml, but the
previous decline of the vl had been rather slow and a
secondary  failure  with  no  further  treatment  options
was imminent. Two further patients (#26 and 31) also
had multiresistant viruses and had repeatedly shown
poor adherence to antiretroviral treatments in the past
with few remaining treatment options. In order to pre-
serve  these  ultimately  remaining  options,  Mvc  was
added  for  greater  likelihood  of  long-term  success.
one patient (#27) received Mvc as an experimental
add-on with the aim of a cd4 T cell count increase, as
the baseline cd4 T cell count was 88 /ﾵl in spite of a
long-term suppressed vl. 
dRuG coMBInaTIons wITH Mvc
at the time of first use, Mvc was combined with oth-
er  (median  2)  salvage  drugs  in  17  /32  cases  (52%).
Mvc was combined with 1 other salvage drug in 13%,
with 2 in 25%, with 3 in 13% and with 4 in 3% of cas-
es.    salvage  drugs  most  frequently  combined  with
Mvc included dRv (n = 14) and Ral (n = 14). oth-
er salvage drugs used were Enf (n = 3), ETR (n = 2)
and TPv (n = 1).
TREaTMEnT REsPonsE
after  initiation  of  Mvc,  a  complete  treatment  re-
sponse was achieved in 24 /32 (75%) patients after 3
months and in 25 /32 (78%) after month 6. The medi-
an increase of cd4 cells after 3 months was 141 /ﾵl,
and 124 /ﾵl after 6 months (Table 2). Patients with
treatment success (complete and partial treatment re-
sponse) had a median cumulative sensitivity score of
2.75 at start of Mvc, while patients with treatment
failure (primary and secondary) had a median score of
2.5. The median time of follow-up for patients with
sustained complete treatment response (n = 17) was
12.1 months. 
In group a, the vl could be fully suppressed in 18
/25 (72%) patients after 3 months (Table 2). In two
cases with only partial response at month 3, the Mvc
containing regimen was continued and complete treat-
ment response was achieved in the long-run (patients
6 and 17). 
In group B, patient 29 received a further intensifica-
tion of its regimen with add-on of ETR after month
3, because of low-level viremia. This patient currently
presents with a stable vl suppression.
a total of 12 out of 32 patients (38%) experienced
treatment failure under combination treatment includ-
ing Mvc. In 2 patients failure of treatment was prima-
ry, while 10 patients showed secondary treatment fail-
ure.
TRoPIsM TEsTInG
all  patients  received  either  genotypic  or  phenotypic
resistance analysis at baseline, i.e. at least once during
the year before receiving Mvc (Table 3). In 13 out of
32 patients a phenotypic tropism result was obtained,
while genotypic tropism testing was performed in 31
patients. Thus, 12 patients received both tests and test
results concurred in 9 (75%) cases. Mvc was started
with a median time of 43 days after genotypic core-
ceptor  testing.  a  sustained  complete  treatment  re-
sponse was achieved in 17 /31 patients (55%) after
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Table 1. Baseline characteristics of patients started on Mvc treatment.
Characteristics Group A1 Group B2 All patients
n = 25 n = 7 n = 32
Gender (f /m) 6 / 19 2 / 5 8 / 24
Median age at start Mvc (years) 47 48 47
Median cd4+T  count at baseline 364 235 306.5
Median vl at baseline 829 <50 copies /ml 280
Median number of previous drug combinations* 9 10 9
Median duration of previous antiretroviral therapy (years) * 10.2 8.5 10.1
Percentage with ccs of oBT ≥ 2 20 / 25 5 / 7 25 / 32
(80%) (71%) (78%)
Median ccs of oBT  2.5 2.0 2.5
*salvage drugs included darunavir, raltegravir, etravirine, enfuvirtide, and tipranavir (dRv, Ral, ETR, Enf and TPv). ccs =
cumulative sensitivity score, 1HIv-Rna detectable at screening, 2HIv-Rna not detectable at screening.
1. Reuter_Umbruchvorlage  14.06.10  20:26  Seite 233EuRoPEan JouRnal of MEdIcal REsEaRcH 234 June 28, 2010
Table 2. characteristics of treatment response.
Characteristics Group A1 Group B2 All patients
(n = 25) (n = 7) (n = 32)
Median duration of follow-up (months) 15 21 16
(n = 25) (n = 7) (n = 32)
Median duration until vl below detection limit (days) 52 - 52
(n = 24)* (n = 24)*
Median increase in cd4+ T-cell count at month 3 112 cells /ﾵl 21 cells /ﾵl 141 cells  / ﾵl
(n = 25) (n = 7) (n = 32)
Median increase in cd4+ T-cell count at month 6 96 cells /ﾵl 88 cells /ﾵl 124 cells /ﾵl
(n = 25) (n = 7) (n = 32)
number of patients with vl below detection limit after 3 months 18 / 25 6 / 7** 24 / 32
number of patients with sustained complete response   12 5 17
(median duration of observation)  (11.5 months) (14.2 months) (12.1 months)
number of patients with secondary treatment failure   82 9
(median duration to failure)  (9.2 months) (10 months) (9.2 months)
number of patients with partial response 30 3
number of patients with primary treatment failure  2- 3
(median duration to failure) (3.5 months) (4.0 months)
*one patient never showed vl suppression (lowest vl under Mvc: 1874 copies /ml).
**In one case vl was detectable at month 3 despite the addition of Mvc, 1HIv-Rna detectable at screening, 2HIv-Rna not
detectable at screening.
Table 3.Tropism test results and response to treatment.
+ = sustained complete treatment response, (+) = partial treatment response, prim. = primary, sec. = secondary, d/M =
dual/mixed.
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after phenotypic tropism testing (Table 3).
The Trofile test had revealed R5 virus in 12 cases,
while  in  one  case,  initial  screening  had  shown  a
dual/mixed  tropism  (patient  4).  The  genotypic  tro-
pism test predicted R5 viruses in 26 /31 (84%) analy-
ses. x4 viruses were predicted in patients #14, 15, 18,
23 and 26. four of the latter would have been predict-
ed  R5  by  the  genotypic  assay  at  a  fPR  of  5%  and
complete suppression of vl has persisted in these 4
patients. 
Tropism testing was additionally performed in 11
out of 12 cases after primary or secondary treatment
failure.  x4  or  dual/mixed  virus  tropism  was  docu-
mented in 6 out of 12 cases. In 5 cases, R5 viruses
persisted despite failure (poor adherence could not be
excluded in 2 cases and a weak oBT was evident in 3
cases). 
safETy PRofIlE
Mvc containing regimens were generally well tolerat-
ed. at 3 or 6 months after starting Mvc, newly elevat-
ed transaminases (< 3x upper normal limit) were not-
ed in 4 patients (#7, 10, 22 and 30) and newly elevated
GGT (< 3x upper normal limit) was noted in 2 pa-
tients (#13 and 16). while patient 10 had replicative
HBv infection, drug adverse events (due to Mvc or
the oBT) could not be excluded as the cause of ele-
vated liver parameters in the remaining cases.
dIscussIon
This prospective, observational study was performed
in an unselected patient population between the years
2005 and 2008. a total of 87 patients were tested for
their viral tropism status and 55 were reported to har-
bour x4 viruses, while 32 started Mvc treatment.
IndIcaTIons foR Mvc usE
available studies indicate that Mvc is a useful thera-
peutic adjunct in heavily pre-treated patients [4, 10]. In
our study, indications for choosing a Mvc-containing
regimen were either intolerance to a previous regimen
or as add-on medication for intensification of the cur-
rent regimen in approximately half of patients, while
patients  with  virological  treatment  failure  comprised
the other half of patients. Treatment failure and side-
effects are well-known causes for a change of the anti-
retroviral regimen. However, the addition of a drug
for further intensification of a current regimen is a
newly emerging treatment strategy. at our institution,
this strategy has become more frequent with the ad-
vent of new drug classes for salvage treatment. add-
on Mvc for regimen intensification was successfully
applied in 12 cases. In 7 cases, vl could only be fully
suppressed after addition of Mvc. In the other 5 cas-
es, the vl was suppressed under the current regimen,
but the situation was judged as unstable due to few re-
maining treatment options and an extensive resistance
pattern.  Here,  a  continued  suppression  of  vl  was
documented for a median duration of observation of
16 months after adding Mvc.
cd4+-cEll counT IncREasE
despite heavy pre-treatment, pronounced increases of
cd4+-cells counts under Mvc have been repeatedly
described. saag and co-workers observed that Mvc in
patients with dual or mixed tropism viral populations
did not result in improved viral suppression, but led to
a  greater  cd4+-cell  count  increase  as  compared  to
placebo [11]. In the MoTIvaTE trials, pooled data
showed a cd4+-cell increase of 124 cells /ﾵl for Mvc
applied twice daily [4]. The median increase of cd4+-
cells  in  our  survey  was  124  cells/ﾵl  after  6  months
(table 2) and was hereby comparable to the numbers
from the MoTIvaTE trials. In addition, our analysis
revealed that in patients with detectable vl at base-
line, the greatest increase of cd4+-cells was observed
during the first 3 months of treatment with a slow in-
crease hereafter. 
a  widely  accepted  theory  for  early  cd4  cell  in-
crease after introduction of aRT is the resolution of
lymphocyte sequestration in tissue sites and redistribu-
tion of these lymphocytes into the blood. This mecha-
nism may explain the early increase of cd4 cells in
group a. 
Interestingly, in patients with suppressed vl at base-
line (group B) the largest increase of cd4+-cells was
observed between months 3 and 6. we may speculate
that this delayed increase of cd4 cells might represent
a different mechanism of immune reconstitution.
TREaTMEnT REsPonsE
despite heavy pre-treatment in 75% of our patients,
72% achieved a full vl-suppression at 12 weeks in pa-
tients with detectable vl at baseline. notably, this suc-
cess rate is higher than the success rates in the MoTI-
vaTE trials, where less than 40% reached full vl-sup-
pression at week 12 [4]. our markedly higher rate of
vl suppression can be explained by the frequent use
of new potent drugs in the oBT, such as dRv, Ral
and ETR. These drugs had not been available in the
MoTIvaTE studies. However, it must be noted that
treatment outcomes may also have been biased due to
the small number of total patients in our cohort.
Treatment failure under a Mvc containing regimen
does not necessarily imply a switch of receptor tro-
pism from R5 to x4. only 4 of our patients had a
documented switch in the genotypic analysis from R5
to x4 using viral strains. In a sub-analysis of the Mo-
TIvaTE trials, x4 viruses were observed in more than
50%  of  patients  under  Mvc  at  the  time  of  failure
[10]. This finding is consistent with the increased sen-
sitivity for detection of low levels of pre-existing virus
binding to cxcR4, when ccR5-tropic variants are se-
lectively suppressed. The predominance of x4-strains
at the time of failure is analogous to the selection of
archived drug-resistant virus leading to reduced effica-
cy when failed antiretroviral therapy is reinitiated after
the interruption of treatment [12]. 
IMPoRTancE of oBT
It was repeatedly shown that potent, fully active new
drugs in the background regimen have an additional
EuRoPEan JouRnal of MEdIcal REsEaRcH June 28, 2010 235
1. Reuter_Umbruchvorlage  14.06.10  20:26  Seite 235beneficial effect when therapy with Mvc is initiated
[10, 13, 14]. In some patients, the original regime did
not lead to vl suppression. However, adding further
salvage drugs or adapting the oBT to newly occurring
mutations  increases  the  chances  of  suppressing  the
vl below the detection limit. In our analysis, 8 out of
32 patients with a new Mvc containing regimen could
not be fully suppressed after month 3. vl could be
successfully suppressed below the detection limit in 1
of  these  patients  after  addition  of  another  salvage
drug (ETR). 
one  objective  measurement  for  the  number  of
available susceptible co-medications is the cumulative
sensitivity score (css) for the oBT. In the css a drug
is only considered fully active if all previous genotypic
analyses have revealed sensitivity [15]. a slightly higher
css at start of Mvc was seen in patients with com-
plete  and  partial  treatment  response  (median  css
2.75) as compared to patients with treatment failure
(median css 2.5). This finding underscores the impor-
tance of a potent oBT in combination with Mvc. 
TRoPIsM TEsTInG
Tropism  testing  is  mandatory  prior  to  the  use  of
Mvc. To date, all major Mvc clinical trials have been
performed with the phenotypic Trofile assay [4, 10],
able to detect minority subpopulations with alternate
tropisms when present at 5 to 10%, or up to 0.3 %
with the new Trofile Es assay. unfortunately, perfor-
mance of the phenotypic Trofile assay is restricted to
one location in california, usa, produces high costs,
requires a minimal vl of 1000 copies /ml and a delay
of 3-6 weeks until receipt of results, hereby prohibit-
ing timely treatment decisions [16, 17]. 
due to the above disadvantages, centers are increas-
ingly applying genotypic tropism testing, whose accu-
racy  is  similar  to  the  Trofile  assay  [18-23].  It  was
shown that genotypic tropism testing is more cost-ef-
fective  and  time-saving  and  can  be  performed  with
low vl [3, 16]. currently, few clinical data on the use
of the genotypic assay are available [21, 22]. The value
of the genotypic assay as an alternative to phenotypic
testing  was  confirmed  in  the  present  study.  a  sus-
tained suppression of viral replication was at least as
frequently achieved after genotypic tropism analysis as
compared to the Trofile test (55% vs. 46%). we found
conscordance between phenotypic and genotypic test
results in 75% of cases (using a fPR of 20%). In anal-
ogy, Poveda and co-workers found a concordance of
the assays in 72% of cases [20]. In general, a good re-
sponse to Mvc in patients with predicted R5 viruses
was documented, irrespective of the tropism test used. 
fPR  is  the  probability  that  “real”  R5  viruses  are
predicted as x4. for the discrimination between R5
and x4 viruses, the fPR is classically set at a high cut-
off-level of 20%. This is a very conservative set point
in order to minimize the risk of predicting a R5 virus
although x4-using viruses are present. using this con-
servative  cutoff  value,  5  patients  had  predicted  x4
viruses. The corresponding fPRs were determined be-
low 20% but above 5% in 4 cases (patients #14, 15,
18, 26). Mvc was used in these patients due to severe-
ly  limited  treatment  options  and  excellent  treatment
results were obtained in all 4 patients. This example
demonstrates that lowering the fPR to 5% may be jus-
tified in selected cases with multiresistant viruses, in
order to preserve Mvc as an important option. using
a cutoff of 5% the concordance between the genotyp-
ic and phenotypic analyses was 92%.
after  treatment  failure,  tropism  testing  was  per-
formed  in  11  /12  cases.  x4  or  dual/mixed  tropism
was documented in 6 /11 cases, while R5-virus per-
sisted despite failure in 5 cases. These findings suggest
that  despite  documented  R5-viruses,  additional  rea-
sons may account for treatment failure of a Mvc con-
taining regimen, including poor treatment adherence
and insufficient potency of the oBT. In failing cases
with R5-persistence, the oBT contained further sal-
vage drugs in 4 out of 5 cases at the time of failure.
as a reason for failure, poor adherence had to be as-
sumed in 2 cases (as a consequence regimen was not
changed), while a weak oBT was evident in 3 cases (as
a consequence further sensitive drugs were added to
the regimen).
Treatment failure occurring despite persistence of
an  R5  receptor  status  has  been  previously  observed
[10] with 43% of patients being R5 at the time of fail-
ure. Resistance to Mvc while maintaining ccR5-tro-
pism  has  been  discussed  as  another  possibility  for
treatment failure, but appears to be a rare event in vivo
[24].
conclusIons
with the recent advent of new treatment options in
HIv-medicine, complete suppression of HI-viral load
has again become an attainable goal for many heavily
pre-treated patients. Mvc containing salvage regimes
achieve relevant cd4+-cell increases and high viral re-
sponse rates. In some patients, the time until com-
plete suppression of vl may be prolonged beyond
the first 3 months of treatment. In clinical routine,
Mvc  is  frequently  combined  with  other  new  anti-
retroviral  drugs,  especially  dRv  and  Ral.  Reasons
for choosing Mvc as a combination partner included
treatment failure and intolerance of the previous anti-
retroviral regimen. In addition, add-on Mvc for regi-
men  intensification  is  a  newly  emerging  treatment
strategy. This option is especially promising because
of the good tolerability and safety profile of Mvc. In
patients with few remaining treatment options it may
be  justified  to  lower  the  cutoff  for  the  fPR  used
when predicting the coreceptor usage from 20% to
5%. Hereby, Mvc can still be applied in selected pa-
tients with otherwise limited treatment options. The
value of the genotypic assay as an evolving alternative
to phenotypic testing was confirmed in the present
study and has become the standard assay for tropism
testing at many institutions.
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